George Kemble - 20 Nov 2025 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Reporting relationship: Executive Chairman, Director
Issuer ticker: SGMT
Reported as of: 20 Nov 2025
Net transaction value: -$289,979
SEC form: 4
Accepted by SEC: 21 Nov 2025, 18:13:11 UTC
Prior SEC filing: 10 Jun 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Rozek, Attorney-in-Fact

Key filing fact

George Kemble filed Form 4 for Sagimet Biosciences Inc. (SGMT) on 21 Nov 2025.

Key facts

This page summarizes George Kemble's Form 4 filing for Sagimet Biosciences Inc. (SGMT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Nov 2025, 18:13.

Change

Previous filing in this sequence was filed on 10 Jun 2025.
Current net transaction value: -$289,979.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001858176 Primary reporting owner

Kemble George

Relationship: Executive Chairman, Director
Address: SAGIMET BIOSCIENCES INC., 155 BOVET RD., SUITE 303, SAN MATEO
Signature: /s/ Elizabeth Rozek, Attorney-in-Fact
Signature date: 21 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGMT transaction

Series A Common Stock

Sale

Transaction value: $289,979
Shares: -37,688
Change %: -32%
Price: $7.69
Shares after: 81,005
Date: 20 Nov 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.27 to $8.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.